Ignite Creation Date:
2025-12-24 @ 5:56 PM
Ignite Modification Date:
2026-03-14 @ 9:04 AM
Study NCT ID:
NCT05862168
Status:
RECRUITING
Last Update Posted:
2023-07-17
First Post:
2023-05-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial
Sponsor:
Weijia Fang, MD
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
Neo-TIME
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None